Jubilant Ingrevia Limited — Updates, 28-01-2025: Press Release

### Investor Presentation Summary

**Financial Highlights:**

Total revenue for Q3'FY25 reached Rs 1,057 Cr, marking a year-on-year increase of 9.4%. EBITDA improved to Rs 148 Cr, reflecting a 41.5% rise year-on-year, resulting in a margin of 14%. Profit after tax surged to Rs 69 Cr, up 80% YoY, contributing to an EPS of Rs 4.4.

**Strategic Initiatives and Growth Drivers:**

The company continues to execute its ambitious Pinnacle 345 vision. The commissioning of the cGMP-compliant Vitamin B3 facility in Bharuch is set to enhance its foothold in the nutraceuticals market. Recent global recognition as part of the World Economic Forum's Global Lighthouse Network emphasizes its commitment to innovation.

**Business Developments:**

Strong performance in the Specialty Chemicals segment, particularly in fine chemicals and choline products, with significant volume growth. However, challenges persist in the Chemical Intermediates segment, driven by sluggish demand in Paracetamol.

**Market Position and Competitive Advantage:**

Jubilant Ingrevia remains a leader in its field, driven by continuous demand improvement in pharmaceuticals and agrochemicals, despite pricing pressures in certain areas. Its focus on cost efficiency and productivity is key to maintaining competitive margins.

**Investor Implications:**

The company’s ongoing investments and strategic initiatives position it well for sustained growth. Positive developments in specialty chemicals and nutrition support a favorable outlook for future performance, highlighting both opportunities and risks that investors should monitor closely.